Tesaro Inc. (TSRO), Breast International Group and the European Organization for Research and Treatment of Cancer announced a partnership for the Phase 3 clinical development of niraparib Monday morning.
Tesaro climbed in early trade Monday and rose further around midday. The stock ended the session higher by 12.01 at $46.22 on strong volume and broke out to a new high for the year.
For comments and feedback: editorial@rttnews.com